A Phase 2 interventional study of Celecoxib in Precancerous Conditions, sponsored by Pfizer. Completed at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-09-29.
Sponsored by Pfizer · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 151 studies in Precancerous Conditions with a site in United States — 6 open to participants now, 12 under way, 2 of them phase 3. Precancerous Conditions · United States.
Among the 151 studies in Precancerous Conditions with a site in United States, this one is the 64th largest by enrollment of the 105 interventional ones that give a count, is one of 6 that started in 2000, is one of 44 in phase 2, and was the 32nd registered.
217 studies on the registry are indexed under Precancerous Conditions; 16 are open to participants now.
Browse Precancerous Conditions studies →6 of the 151 studies in Precancerous Conditions with a site in United States are open now. Recruiting first, the newest first:
Orca Biosystems, Inc. · Sites in United States
Ages 18+
Sun Pharmaceutical Industries, Inc. · Sites in United States
Ages 18–85
Sun Pharmaceutical Industries, Inc. · Sites in United States
Ages 18–85
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
Vanderbilt University Medical Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 12 Precancerous Conditions studies recruiting now, 6 (50%) set no upper age limit and 1 (8%) stops at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
151 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 33 · Phase 2 52 · Phase 3 23 · Phase 4 1
First in 1971; this study’s year is marked. 6 started in 2000.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 42 is below the median of 70 across 143 interventional studies indexed under Precancerous Conditions.
Median enrollment 58 across the 105 interventional studies, 302 across the 25 observational. Of the 125 that completed or were terminated, 48 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 151 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 146 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 1 study filed under Precancerous Conditions — fewer than ten, so there is no comparison to draw.
4 of the studies in Precancerous Conditions with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07144345Phase 3Sun Pharmaceutical Industries, Inc.Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp | 2027-01 |
| NCT07144852Phase 3Sun Pharmaceutical Industries, Inc.Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities | 2027-01 |
| NCT06001385Center for International Blood and Marrow Transplant ResearchHLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis | 2026-12-24 |
| NCT07216443Orca Biosystems, Inc.Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | 2027-11 |
Add all 4 to your calendar (.ics) → With an account.
Among the 151 studies in Precancerous Conditions with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Reduction in size and number of oral premalignant lesions
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
To evaluate the efficacy of celecoxib in subjects with Early or Advanced oral premalignant lesion (OPL)
by both clinical response (reduction in size of all lesions,
prevention of growth in the index lesion and of any new lesions)
and histological response (change in histological grade).
To evaluate the safety of chronic multiple dosing of celecoxib in this patient population.
To evaluate the treatment effects in modulating the expression of genomic and proliferative markers after 12 weeks of treatment with study drug, followed by 12 weeks off study drug.
The record gives a start of Nov 2000 and a completion of Apr 2004. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Celecoxib